疲劳在识别发生疾病进展的NASH合并晚期纤维化患者中的潜在作用
研究纳入活检确诊的NASH合并桥接纤维化(F3)或代偿性肝硬化(F4)患者,随访至多2年,用CLDQ-NASH疲劳域评分(1-7分,评分越低疲劳越重)量化基线疲劳。F3患者中较低疲劳评分与肝脏相关事件风险升高相关(校正HR 0.85,95%CI 0.74-0.97,P=.02),F4患者中与肝失代偿风险升高相关(校正HR 0.62,95%CI 0.48-0.81,P=.0004)。
要点
- NASH合并F3患者中15%(n=123)出现肝脏相关事件,F4患者中3.5%(n=31)出现肝失代偿。
- F3发生肝脏相关事件者基线疲劳评分较低:4.47±1.36 vs 4.83±1.35(P=.0091)。
- F4发生肝失代偿者基线疲劳评分较低:3.74±1.31 vs 4.59±1.43(P=.0011)。
核心结论
- 基线疲劳越重与NASH相关晚期纤维化和肝硬化患者不良临床事件风险越高相关。
研究设计与样本
- 活检确诊NASH合并桥接纤维化(F3)或代偿性肝硬化(F4)的患者随访至多2年,共1679例,其中F3 802例、F4 877例(58±9岁,40%男性,74%为2型糖尿病)。
- 基线采用CLDQ-NASH疲劳域评分(范围1-7,评分越低表示疲劳越重)量化疲劳,用Cox比例风险模型分析至肝脏相关临床事件的时间。
- F3的肝脏相关事件定义为进展为组织学肝硬化或肝失代偿,F4定义为肝失代偿。
主要发现
- 中位随访16个月(四分位距14-18)期间,F3患者15%(n=123)发生肝脏相关事件,F4患者3.5%(n=31)发生肝失代偿。
- F3患者基线疲劳评分均值4.77±1.36;发生肝脏相关事件者基线评分较低:4.47±1.36 vs 4.83±1.35(P=.0091)。
- F4患者基线疲劳评分均值4.56±1.44;随访中发生肝失代偿者评分较低:3.74±1.31 vs 4.59±1.43(P=.0011)。
- 校正混杂因素后,较低疲劳评分与肝脏相关事件或失代偿事件风险的关联仍显著:F3每降低1分校正HR 0.85(95%CI 0.74-0.97,P=.02),F4校正HR 0.62(95%CI 0.48-0.81,P=.0004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Fatigue is common in patients with advanced liver disease. We investigated fatigue and clinical outcomes among patients with advanced nonalcoholic steatohepatitis (NASH). METHODS: In this study, patients with biopsy confirmed NASH and bridging fibrosis (F3) or compensated cirrhosis (F4) were followed for up to 2 years. The Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) fatigue domain at baseline (range, 1-7; lower score indicating worse fatigue) quantified fatigue. The Cox proportional hazards model was used to study time to liver-related clinical events (progression to histologic cirrhosis or hepatic decompensation in F3, hepatic decompensation in F4). RESULTS: Of the 1679 NASH patients with fibrosis, 802 had F3 and 877 had F4 (58 ± 9 years of age, 40% male, 74% type 2 diabetes). During median follow-up of 16 months (interquartile range, 14-18), 15% (n = 123) of NASH F3 patients experienced liver-related events and 3.5% (n = 31) of NASH F4 patients experienced hepatic decompensation. Mean baseline CLDQ-NASH fatigue score in F3 patients was 4.77 ± 1.36; NASH F3 patients who experienced liver-related events had lower baseline scores: 4.47 ± 1.36 vs 4.83 ± 1.35 (P = .0091). The mean fatigue score in F4 was 4.56 ± 1.44; these scores were lower in patients who decompensated in follow-up: 3.74 ± 1.31 vs 4.59 ± 1.43 (P = .0011). The association of lower fatigue scores and risk of liver-related or decompensation events was significant after adjustment for confounders (adjusted hazard ratio per 1 point in fatigue score in F3, 0.85; 95% confidence interval, 0.74-0.97; P = .02; adjusted hazard ratio in F4, 0.62; 95% confidence interval, 0.48-0.81; P = .0004). CONCLUSION: Worse fatigue at baseline is associated with a higher risk of adverse clinical events in patients with NASH-related advanced fibrosis and cirrhosis.
引用
- Younossi ZM, Stepanova M, Myers RP, et al. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression. Clin Gastroenterol Hepatol. 2022. PMID: 35533993. doi:10.1016/j.cgh.2022.04.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。